Biology subjects

Wahl-Schott, C.

Publications and source records attributed to Wahl-Schott, C..

3 recordsLinked to original sources

bioRxiv2026

CCZ1 is a modulator of TPC2 activity and melanoma cell migration

The small GTPase RAB7a is a key regulator of melanoma progression by enhancing the activity of the endolysosomal two-pore cation channel TPC2. In this study, we demonstrate that CCZ1--a core component of the RAB7a guanine nucleotide exchange factor (GEF) complex--is essential for mediating this RAB7a-dependent enhancement of TPC2. Unexpectedly, we find that constitutively active (GTP-locked) RAB7a fails to bind and regulate TPC2 in the absence of CCZ1, indicating that CCZ1 contributes to the RAB7a-TPC2 interaction through mechanisms beyond its GEF activity. Furthermore, the CCZ1 facilitated GTPase-activating function on RAB5 is dispensable for modulating TPC2. Notably, in the absence of CCZ1, TPC2 exhibits increased affinity for its agonist, PI(3,5)P2, along with markedly upregulated channel activity. In melanoma cell lines, this upregulation enhances migratory capacity. Our findings identify CCZ1 as a functional inhibitor of TPC2 and highlight its critical role in regulating cancer cell migration.

physiology↗

bioRxiv2025

Differential contribution of HCN1 and HCN4 to the synchronisation of sinoatrial pacemaker cells

The hearts ability to beat with high precision, with a regular and steady rhythm relies on the synchronised activity of pacemaker cells in the sinoatrial node (SAN), which communicate with one another through gap junctions. This process ensures that electrical impulses are organised and reach a critical mass to ignite the electrical activity of the surrounding atrial tissue and trigger the regular heartbeat. HypothesisWe hypothesise that hyperpolarisation-activated, cyclic nucleotide-gated (HCN) channels play a pivotal role in maintaining this synchronisation process. This idea aligns with the well-established role of HCN channels in stabilising the membrane potential in the voltage range of the slow diastolic depolarisation, counteracting voltage fluctuations and effectively filtering out variations in the beating rate from neighbouring cells. AimWe focus on two specific HCN channel subtypes--HCN1 and HCN4--and their contributions to the rapid synchronisation of pacemaker cells, a phenomenon known as phasic entrainment. Using two HCN channel-mutant mouse models, we dissect the distinct roles of HCN1 and HCN4 in this process. MethodsWe employed patch-clamp electrophysiology to determine phase response curves (PRCs) to predict the ability of single cells to interact in the SAN. Using computer simulations, the behaviour of the SAN at the network level was determined. ResultsWe found that HCN1, but not HCN4, is essential for the fast synchronisation of pacemaker cells in the SAN and propose a mechanism by which HCN1 channels regulate this process. ConclusionThese findings highlight HCN1 as a critical component for ensuring the precise and rapid coordination needed for synchronisation of the SAN, for a regular and consistent heartbeat. Translational perspectiveOur work provides essential insights into the cellular and molecular mechanisms governing SAN function and lays the groundwork for several clinically relevant applications. Understanding how If blockers may affect heart rate and rhythm stability is crucial for assessing potential side effects of current and future subtype-specific HCN channel inhibitors. Moreover, our findings could support new diagnostic strategies for detecting patients at risk of SAN dysfunction. Ultimately, these findings pave the way for innovative therapeutic approaches, including targeted channel modulation and future cell or gene therapies to restore pacemaker stability.

physiology↗

bioRxiv2024

A genome-wide RNA interference screening reveals protectiveness of SNX5 knockdown in a Parkinson`s disease cell model

BackgroundAlpha-synuclein is a major player in the pathophysiology of a group of diseases called synucleinopathies, which include Parkinsons disease, dementia with Lewy bodies, and multiple system atrophy. To date, there is no disease-modifying therapy available for these synucleinopathies. Furthermore, the intracellular mechanisms by which alpha-synuclein confers toxicity are not yet fully understood. Therefore, it is of utmost importance to investigate the pathophysiology of alpha-synuclein-induced toxicity in order to identify novel molecular targets for the development of disease-modifying therapies. MethodsIn the present study, we performed the first genome-wide siRNA modifier screening in a human postmitotic neuronal cell model using alpha-synuclein-induced toxicity as read-out. In a multi-step approach, we identified several genes, whose knockdown protected from alpha-synuclein-induced toxicity. The main hit was further validated by different methods, including immunofluorescence microscopy, qPCR, and Western blot. ResultsThe highest protection was achieved by knockdown of SNX5, which encodes the SNX5 protein, a component of the retromer complex. We confirmed the protective efficacy of SNX5 knockdown with an independent siRNA system. SNX5 protein is part of SNX-BAR heterodimers, which are part of the retromer complex. We found that extracellular and overexpressed intracellular alpha-synuclein led to fragmentation of the trans-Golgi network, which was prevented by SNX5 knockdown by confining alpha-synuclein in early endosomes. ConclusionIn summary, our data suggest that SNX5 plays an important role in trafficking and toxicity of alpha-synuclein. Therefore, SNX5 appears to be a possible target for therapeutic interventions in synucleinopathies.

neuroscience↗